WAVEMAN · COMPANY

KLRA · Kailera Therapeutics, Inc.

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475

← ALL COMPANIES

KLRA

Name: Kailera Therapeutics, Inc. (KLRA) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Kailera Therapeutics, Inc.

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0002096997

CLUSTER · 5 INSIDERSACTIVIST 13D☆ WATCH

INSIDER NET · 180D

$326.8M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

101

13F, latest reported quarter

REVENUE GROWTH

XBRL, annual

NET MARGIN

CONVERSIONS · 180D

codes C/M, not in net · $200.0K priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net +$326.8M over 180 days

+$326.8M of it by a 10%+ holder

the highest in Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

101 funds added or opened last quarter

more than 65% of Pharma & Biotech

REVENUE

no revenue reported in any filing

MARGIN

no margin: this company reports no revenue to divide by

BUYBACKS

no share repurchases reported

SHORT

5.1% of shares outstanding short · 13.2 days to cover · settled 2026-07-31

more than 55% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

5 insiders independently bought a net $326.8M — no planned sales are queued against it.

101 funds added or opened positions in the latest 13F quarter, of 101 holders.

BCLS Fund IV Investments, L.P. disclosed a 5%+ stake (17.43%) in the last six months.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -39.0%

-39.0%12M

INSIDER BUY13D/G STAKE

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

5 insiders reported buying shares.

The record shows a net $326.8M bought by insiders over 180 days, 101 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Kailera Therapeutics, Inc. insiders bought a net $326.8M of stock across 5 Form 4 purchases and sales, with 5 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER

FILED

VALUE

RTW INVESTMENTS, LP

—

BUY

2026-04-20

500,000.0

$8.0M

BCPE Perseus Investor, LP

—

BUY

2026-04-20

8,398,438.0

$134.4M

Koppel Adam

Director

BUY

2026-04-20

1,562,500.0

$25.0M

BCLS Fund IV Investments GP, LLC

—

BUY

2026-04-20

1,562,500.0

$25.0M

Kaplan Andrew T.

Director

BUY

2026-04-20

8,398,438.0

$134.4M

5 TRANSACTIONS ON RECORD · THIN RECORD, READ IT AS SUCH

Showing the most recent few. Create a free account to see the full history, the screener and CSV export, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

Bain Capital Investors LLC

26,255,581.0 sh

$578.4M

Bain Capital Life Sciences Investors, LLC

22,583,268.0 sh

$497.5M

RTW INVESTMENTS, LP

10,776,820.0 sh

$237.4M

CANADA PENSION PLAN INVESTMENT BOARD

7,304,688.0 sh

$160.9M

Atlas Venture Life Science Advisors, LLC

5,171,282.0 sh

$113.9M

5%+ owners

13D = intent to influence · 13G = passive

BCLS Fund IV Investments, L.P.

ACTIVIST 13D · 2026-04-23

17.43%

BCPE Perseus Investor, LP

ACTIVIST 13D · 2026-04-23

20.27%

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

THE HARTFORD HEALTHCARE FUND

$4.7M POSITION · AS OF 2026-04-30

0.6%

Federated Hermes Kaufmann Small Cap Fund

$12.5M POSITION · AS OF 2026-04-30

0.4%

Franklin Biotechnology Discovery Fund

$3.7M POSITION · AS OF 2026-04-30

0.4%

VANGUARD HEALTH CARE FUND

$53.2M POSITION · AS OF 2026-04-30

0.1%

The Hartford Small Cap Growth Fund

$200.0K POSITION · AS OF 2026-04-30

0.1%

U.S. Small Cap Equity Fund

$270.9K POSITION · AS OF 2026-04-30

0.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK